Last updated on April 2007

RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease


Brief description of study

The objective of this study is to evaluate an antibiotic therapy called Rifalazil to determine its effect on hardening of the carotid arteries.

Detailed Study Description

To evaluate the effect of treatment with rifalazil versus placebo taken once weekly for 12 weeks on carotid atherosclerotic disease progression in patients who test positive for Chlamydia pneumoniae. Measurements of the carotid artery wall (intima-media thickness) and plaque characteristics will be evaluated with high-resolution magnetic resonance imaging (MRI) and carotid ultrasound. at Baseline and at 6,12 and 18 months following initiation of drug treatment in Chlamydia pneumoniae seropositive patients with a history of atherosclerotic disease. Biomarkers will be collected throughout the study. Safety will be evaluated by the collection and analysis of laboratory parameters, vital signs, electrocardiograms, physical examination and adverse events. Seventy two patients will be enrolled in this study. There will be a total of approximately 7-9 visits which will occur over an 18 month period.

Clinical Study Identifier: NCT00385385

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Emelia Klonowski Klonowski

Thoracic & Cardiovascular Healthcare Foundation
Lansing, MI United States
  Connect »

Emelia Klonowski Klonowski

St. Francis Hospital
Roslyn, NY United States
  Connect »

Emelia Klonowski Klonowski

Stony Brook University Medical Center
Stony Brook, NY United States
  Connect »

Emelia Klonowski Klonowski

Baylor College of Medicine
Houston, TX United States
  Connect »

Emelia Klonowski Klonowski

Swedish Medical Center
Seattle, WA United States
  Connect »

Emelia Klonowski Klonowski

Robarts Research Institute
London, ON Canada
  Connect »